PDGFRB and neoplasm: Inhibit multiple intracellular and cell surface kinases in the Ras/Raf/MEK/ERK signaling pathways. The drug inhibits Raf-1, B-Raf, and kinase activity, PDGFR-β, VEGFR 2, hepatocyte factor receptor (c-KIT), and other proteins to inhibit tumor angiogenesis.